Zobrazeno 1 - 10
of 434
pro vyhledávání: '"Afshin, Dowlati"'
Autor:
Demitrios Dedousis, Annie L. Zhang, Anastasia N. Vassiliou, Shufen Cao, Deepthi Yammani, Ravi K. Kyasaram, John P. Shanahan, Melissa C. Keinath, Melinda L. Hsu, Pingfu Fu, Afshin Dowlati, Alberto J. Montero
Publikováno v:
Cancer Medicine, Vol 12, Iss 12, Pp 13086-13099 (2023)
Abstract Background Patients with certain autoimmune conditions are at a reduced risk of developing breast cancer compared to the general population. Despite this, little is known about outcomes in patients with breast cancer who have a concurrent au
Externí odkaz:
https://doaj.org/article/48f597776f8d4666879c67d21dc5d57b
Autor:
Mohammad A. Shatat, Betsy Gauthier, Suzy Yoon, Eric Yuan, Peiying Yang, Goutham Narla, Afshin Dowlati, Richard T. Lee
Publikováno v:
Cancer Medicine, Vol 12, Iss 7, Pp 8378-8387 (2023)
Abstract Background Small‐cell lung cancer (SCLC) is the deadliest form of lung cancer but lacks targeted therapies. Methods We studied the effect of the natural product mistletoe lectin (ML) in pre‐clinical models of SCLC, focusing on cell lines
Externí odkaz:
https://doaj.org/article/47d4d8de8a9249e683d144928f16b31a
Publikováno v:
Molecular Oncology, Vol 15, Iss 12, Pp 3545-3558 (2021)
High‐grade neuroendocrine carcinoma of gynecologic origin (NEC‐GYN) is a highly aggressive cancer that often affects young women. The clinical management of NEC‐GYN is typically extrapolated from its counterpart, small cell carcinoma of the lun
Externí odkaz:
https://doaj.org/article/ffae59a46950433a8f22dbd047b6eba3
Autor:
Sarina Piha-Paul, MD, George Simon, MD, Chandra P. Belani, MD, Heman Chao, PhD, Kim Gaspar, PhD, Brenda Lee, MSc, Afshin Dowlati, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 11, Pp 100408- (2022)
Introduction: L-DOS47, a targeted urease–anti-CEACAM6 immunoconjugate, alters the acidity of the tumor microenvironment by increasing local ammonia production. In vitro, the cytotoxic effects of L-DOS47 were additive when combined with pemetrexed a
Externí odkaz:
https://doaj.org/article/b0e5a55630a34b9db3db56cd15ad246c
Autor:
Demitrios Dedousis, MD, Anastasia N. Vassiliou, MS, Shufen Cao, PhD, Deepthi Yammani, BS, Ravi K. Kyasaram, MS, John Shanahan, BS, Melissa C. Keinath, PhD, Annie L. Zhang, MD, Melinda L. Hsu, MD, Pingfu Fu, PhD, Afshin Dowlati, MD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 9, Pp 100375- (2022)
Introduction: Autoimmune disease has both a predisposing and a protective effect toward malignancy. Though studies have investigated the risk of malignancy in patients with autoimmune disease, there is limited research on how autoimmunity affects sur
Externí odkaz:
https://doaj.org/article/e0b837eeef3a4f6e8098c61fecd54a60
Autor:
Michelle Treasure, Barbara Daly, Shufen Cao, Pingfu Fu, Augustine Hong, Elizabeth Weinstein, Jessica Surdam, Neal J. Meropol, Afshin Dowlati
Publikováno v:
Cancer Medicine, Vol 10, Iss 13, Pp 4312-4321 (2021)
Abstract Purpose Patients enrolled in Phase 1 clinical trials have typically exhausted standard therapies and often are choosing between a clinical trial and hospice care. Significant symptom burden can result in early trial discontinuation and confo
Externí odkaz:
https://doaj.org/article/9e808bed63da48019eec6c5bd1355953
Autor:
Justin D. Finkle, Hala Boulos, Terri M. Driessen, Christine Lo, Richard A. Blidner, Ashraf Hafez, Aly A. Khan, Ariane Lozac’hmeur, Kelly E. McKinnon, Jason Perera, Wei Zhu, Afshin Dowlati, Kevin P. White, Robert Tell, Nike Beaubier
Publikováno v:
npj Precision Oncology, Vol 5, Iss 1, Pp 1-12 (2021)
Abstract Liquid biopsy is a valuable precision oncology tool that is increasingly used as a non-invasive approach to identify biomarkers, detect resistance mutations, monitor disease burden, and identify early recurrence. The Tempus xF liquid biopsy
Externí odkaz:
https://doaj.org/article/439e514d758c4462a85579f192a11c43
Autor:
Avirup Guha, Prantesh Jain, Michael G. Fradley, Daniel Lenihan, Jahir M. Gutierrez, Chhavi Jain, Marcos deLima, Jill S. Barnholtz‐Sloan, Guilherme H. Oliveira, Afshin Dowlati, Sadeer Al‐Kindi
Publikováno v:
Cancer Medicine, Vol 10, Iss 12, Pp 3862-3872 (2021)
Abstract Background Cardiovascular adverse events (CVAEs) associated with BRAF inhibitors alone versus combination BRAF/MEK inhibitors are not fully understood. Methods This study included all adult patients who received BRAF inhibitors (vemurafenib,
Externí odkaz:
https://doaj.org/article/7d4bbd84fa12427dbc25a5c503168be7
Autor:
Dong-Wan Kim, MD, PhD, Shirish Gadgeel, MD, Scott N. Gettinger, MD, Gregory J. Riely, MD, PhD, Geoffrey R. Oxnard, MD, Tarek Mekhail, MD, Peter Schmid, MD, PhD, Afshin Dowlati, MD, Rebecca S. Heist, MD, MPH, Antoinette J. Wozniak, MD, Jatinder Singh, PhD, Edward Cha, MD, PhD, Jessica Spahn, PhD, Sai-Hong Ignatius Ou, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100367- (2022)
Introduction: Alectinib is a preferred first-line treatment option for advanced ALK-positive NSCLC. Combination regimens of alectinib with immune checkpoint inhibitors are being evaluated for synergistic effects. Methods: Adults with treatment-naive,
Externí odkaz:
https://doaj.org/article/ef3f254cb8784bd19307c98d578cc81c
Autor:
Jonathan W. Goldman, Minal Barve, Jyoti D. Patel, Antoinette Wozniak, Afshin Dowlati, Alexander Starodub, Taofeek K. Owonikoko, William Edenfield, Scott A. Laurie, Daniel Da Costa, Satwant Lally, Martina Koch, Matthew P. Kosloski, David Hoffman, Grace K. Dy
Publikováno v:
Clinical and Translational Science, Vol 14, Iss 2, Pp 664-670 (2021)
Small cell lung cancer (SCLC) is a leading cause of cancer death worldwide, with few treatment options. Rovalpituzumab tesirine (Rova‐T) is an antibody‐drug conjugate that targets delta‐like 3 on SCLC cells to deliver a cytotoxic payload direct
Externí odkaz:
https://doaj.org/article/accac0c4d8ab4b6a908935af63ca37f0